Ernesto Persona-Perez

Gasteiz / Vitoria, PV, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Real-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort.

Real-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort.

Journal: Frontiers in oncology
Published: June 11, 2026

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Journal: Blood cancer journal
Published: March 26, 2024

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 18, 2023

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.

Journal: Hematology (Amsterdam, Netherlands)
Published: February 21, 2023

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.

Journal: Blood cancer journal
Published: August 23, 2021

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.

Journal: European journal of haematology
Published: July 20, 2021

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Journal: PloS one
Published: April 23, 2021

Primary plasma cell leukaemia presenting with flower-shaped nuclei.

Primary plasma cell leukaemia presenting with flower-shaped nuclei.

Journal: British journal of haematology
Published: February 22, 2021

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.

Journal: Blood cancer journal
Published: January 18, 2021

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.

Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2020

Urgent and unexpected findings in oncology and hematology patients: A practical approach to imaging.

Urgent and unexpected findings in oncology and hematology patients: A practical approach to imaging.

Journal: Radiologia
Published: December 29, 2020
Showing 1-12 of 19

Last Updated: 09/26/2026